Gemfibrozil is a prescription medication classified as a fibric acid derivative used primarily to lower triglyceride levels and modestly increase high-density lipoprotein cholesterol. It functions by activating peroxisome proliferator-activated receptor alpha to enhance fatty acid oxidation and reduce triglyceride synthesis in the liver. The drug inhibits lipoprotein lipase activity which slows the clearance of triglyceride-rich particles from plasma. Through these mechanisms it modestly raises high-density lipoprotein cholesterol while decreasing low-density lipoprotein cholesterol to a lesser extent. Gemfibrozil is absorbed in the intestines and metabolized by the liver where it exerts its lipid-lowering effects through hepatic pathways. Its pharmacological action involves increasing the activity of adenosine monophosphate-activated protein kinase that regulates lipid metabolism. The medication is indicated for chronic management of dyslipidemia in patients at risk for cardiovascular events. Overall its role is to alter lipid profiles by influencing hepatic lipid processing and secretion.

Gemfibrozil is a medication used to lower high triglyceride levels in the blood. It belongs to a class of drugs called fibrates that act primarily on the peroxisome proliferator activated receptor alpha. Activation of this receptor increases the expression of enzymes that break down fats and reduces the liver's production of triglycerides. The drug also enhances the removal of triglycerides from the bloodstream by the kidneys and intestine. By decreasing circulating triglyceride concentrations it helps prevent pancreatitis and supports overall cardiovascular health. These combined actions lower triglyceride levels without directly affecting cholesterol.

The most common side effects of this medication include fatigue and mild headache. Patients often report a low grade fever that resolves within a day or two. Some individuals experience mild nausea that may accompany changes in appetite. Muscle aches are reported by a notable portion of users during the first week. A sore throat can develop as the body adjusts to the treatment. Diarrhea may occur in occasional cases and is usually short lived. Dizziness or light headedness can be noted especially after the initial dose. These reactions are generally transient and do not require medical attention if they remain mild.

The most common side effects often involve mild reactions such as headache, nausea, or dizziness. They usually resolve on their own without lasting consequences. Some people may experience temporary fatigue or mild fever. These symptoms are generally short-lived and not indicative of serious complications. Monitoring how the body responds helps identify patterns of tolerance. Understanding typical responses allows individuals to make informed observations.